New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly.

Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI ...

Oxygen, crucial for cellular respiration, is affected by pressure variations within a bioreactor, with higher pressure at the bottom leading to increased oxygen solubility. This heterogeneity is ...

In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies ...

CEO Peter Anastasiou describes the science behind Capsida’s platform, current pipeline, and why they chose to manufacture in-house.

Tom Chalberg, Ph.D., co-founder of Genascence, explains how gene therapies are moving beyond the confines of rare diseases and into a wider range of indications.

LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous ...

Over the last 15 years, biopharmaceutical compliance departments, and chief compliance officers, have been better resourced, with more direct reporting lines to company leadership, than ever before. A ...